Newsletters and Deep Dive digital magazine
Beijing-based pharma, BeiGene’s
BeiGene’s plans for an early approval for BTK inhibitor zanubrutinib in the US and to start challenging Janssen/AbbVie’s blockbuster Imbruvica have suffered a setback.
Inhaled cannabinoids have been shown to perform better than placebo in providing pain relief for people suffering from acute migraine, according to a new clinical trial.
Today, pharma brand planning teams can benefit from technology platforms that aggregate data and automate analyses, helping unlock insights on the market landscape and clinical environment